FUSN Stock - Fusion Pharmaceuticals Inc.
Unlock GoAI Insights for FUSN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $2.07M | $1.46M | $1.44M | N/A | N/A |
| Gross Profit | $723,000 | $-57,434,000 | $-54,917,000 | $-482,000 | $-290,000 |
| Gross Margin | 35.0% | -3931.1% | -3813.7% | N/A | N/A |
| Operating Income | $-99,232,000 | $-88,034,000 | $-82,015,000 | $-37,935,000 | $-18,220,000 |
| Net Income | $-94,897,000 | $-87,612,000 | $-81,047,000 | $-78,333,000 | $-16,189,000 |
| Net Margin | -4588.8% | -5996.7% | -5628.3% | N/A | N/A |
| EPS | $-1.45 | $-2.00 | $-1.90 | $-3.56 | $-0.10 |
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 27th 2023 | Raymond James | Upgrade | Strong Buy | $15← $12 |
| September 29th 2023 | Oppenheimer | Initiation | Outperform | $13 |
| June 23rd 2023 | Raymond James | Initiation | Outperform | $13 |
| December 1st 2022 | B. Riley Securities | Resumed | Buy | $10 |
| November 30th 2022 | SVB Leerink | Initiation | Outperform | $6 |
| September 16th 2022 | Truist | Initiation | Buy | $10 |
| July 6th 2022 | William Blair | Initiation | Outperform | - |
Earnings History & Surprises
FUSNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 7, 2024 | $-0.38 | $-0.40 | -5.3% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $-0.34 | $-0.39 | -14.7% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.40 | $-0.25 | +37.5% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.39 | $-0.38 | +2.6% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.29 | $-0.45 | -55.2% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-0.57 | $-0.55 | +3.5% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.52 | $-0.55 | -5.8% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.53 | $-0.44 | +17.0% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.50 | $-0.46 | +8.0% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.47 | $-0.40 | +14.9% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.60 | $-0.45 | +25.0% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.39 | $-0.63 | -61.5% | ✗ MISS |
Q2 2021 | May 11, 2021 | $-0.29 | $-0.42 | -44.8% | ✗ MISS |
Q1 2021 | Mar 25, 2021 | $-0.19 | $-0.32 | -68.4% | ✗ MISS |
Q4 2020 | Nov 10, 2020 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Q3 2020 | Aug 11, 2020 | $-0.50 | $-18.91 | -3682.0% | ✗ MISS |
Q2 2020 | Jun 26, 2020 | — | $-0.39 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.25 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.03 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.16 | — | — |
Latest News
Frequently Asked Questions about FUSN
What is FUSN's current stock price?
What is the analyst price target for FUSN?
What sector is Fusion Pharmaceuticals Inc. in?
What is FUSN's market cap?
Does FUSN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to FUSN for comparison